Vasopressin Patent Expiration
Vasopressin is Used for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. It was first introduced by Endo Operations Ltd
Vasopressin Patents
Given below is the list of patents protecting Vasopressin, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Vasostrict | US10010575 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9375478 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9687526 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9744209 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9744239 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9750785 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9919026 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9925233 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9925234 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9937223 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9962422 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9968649 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9974827 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
Vasostrict | US9981006 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Endo Operations |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vasopressin's patents.
Latest Legal Activities on Vasopressin's Patents
Given below is the list recent legal activities going on the following patents of Vasopressin.
Event | Date | Patent/Publication |
---|---|---|
![]() | ||
Payment of Maintenance Fee, 8th Year, Large Entity | 10 Nov, 2023 | US9375478 |
Email Notification | 28 May, 2022 | US9925234 |
Change in Power of Attorney (May Include Associate POA) | 27 May, 2022 | US9925234 |
Correspondence Address Change | 26 May, 2022 | US9925234 |
Payment of Maintenance Fee, 4th Year, Large Entity | 09 Dec, 2021 | US10010575 |
Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9968649 |
Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9974827 |
Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9981006 |
Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9962422 |
Payment of Maintenance Fee, 4th Year, Large Entity | 09 Sep, 2021 | US9937223 |
Coming Soon
Patent Strength Analyzer
![](/_nuxt/img/PatentAnalyzerAd.722976d.jpg)
YesNo
Thank you for your response 🥳
Vasopressin Generics
Several generic applications have been filed for Vasopressin. The first generic version for Vasopressin was by Eagle Pharmaceuticals Inc and was approved on Dec 15, 2021. And the latest generic version is by Dr Reddys Laboratories Ltd and was approved on May 8, 2024.
Given below is the list of companies who have filed for Vasopressin generic.
1. CIPLA
Cipla Ltd has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Cipla.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20UNITS/100ML (0.2UNITS/ML) | solution | Prescription | INTRAVENOUS | AP | Dec 6, 2023 |
2. AMNEAL
Amneal Eu Ltd has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Amneal.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20UNITS/ML (20UNITS/ML) | solution | Prescription | INTRAVENOUS | AP | Aug 5, 2022 |
3. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Dr Reddys.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20UNITS/ML (20UNITS/ML) | solution | Prescription | INTRAVENOUS | AP | May 8, 2024 |
4. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20UNITS/ML (20UNITS/ML) | solution | Prescription | INTRAVENOUS | AP | Feb 9, 2024 |
5. AMPHASTAR PHARMS INC
Amphastar Pharmaceuticals Inc has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Amphastar Pharms Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20UNITS/ML (20UNITS/ML) | solution | Prescription | INTRAVENOUS | AP | Jul 18, 2022 |
6. EAGLE PHARMS
Eagle Pharmaceuticals Inc has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Eagle Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20UNITS/ML (20UNITS/ML) | solution | Prescription | INTRAVENOUS | AP | Dec 15, 2021 |
7. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20UNITS/ML (20UNITS/ML) | solution | Prescription | INTRAVENOUS | AP | Aug 15, 2022 |
8. FRESENIUS KABI USA
Fresenius Kabi Usa Llc has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20UNITS/ML (20UNITS/ML) | solution | Prescription | INTRAVENOUS | AP | May 26, 2023 |